CVI Holdings’s Moleculin Biotech MBRX Stock Holding History

CVI Holdings’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-8	Closed	-$294K	–	70
2019 Q1	$294K	Buy	+8	New	+$477K	0.28%	28

Other funds holding MBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Whitegate Investment Counselors Concord, New Hampshire $351M AUM 16.12% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

CVI Holdings's MBRX Position: Q2 2019 in Review

CVI Holdings sold out of Moleculin Biotech (MBRX) in Q2 2019, closing a stake of 8 shares — an estimated $294K sold.

CVI Holdings first reported a position in MBRX in Q1 2019 and held it in 1 quarter. The position peaked at $294K in Q1 2019. 9 funds tracked by Wall St. Rank hold MBRX as of Q2 2019.

CVI Holdings reported no remaining Moleculin Biotech position as of Q2 2019 after selling out during the quarter.
CVI Holdings sold 8 Moleculin Biotech shares in Q2 2019, an estimated $294K.
CVI Holdings first reported a position in Moleculin Biotech in Q1 2019 and held it in 1 quarter.
CVI Holdings's Moleculin Biotech position peaked at $294K in Q1 2019.
9 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2019.

Based on CVI Holdings's 13F filing for Q2 2019, filed 14 Aug 2019.